secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2025-12-16T23:59:59+00:00
Accession:  0000078003-25-000167
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer revises FY2025 revenue to ~$62B (from $61-64B), provides FY2026 EPS guidance $2.80-3.00
--------------------------------------------------------------------------------

- Revised FY2025 revenue guidance to ~$62.0B from prior $61-64B; reaffirmed adjusted diluted EPS $3.00-3.15.
- FY2026 revenue guidance $59.5-62.5B; adjusted diluted EPS $2.80-3.00; tax rate ~15% vs ~11%.
- COVID-19 product revenues ~$5.0B in 2026 (vs ~$6.5B in 2025); LOE impact ~$1.5B.
- Adjusted SI&A $12.5-13.5B, R&D $10.5-11.5B in 2026; investing in PD-1 x VEGF bispecific and Metsera programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800325000167/0000078003-25-000167-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800325000167/pfe-20251216.htm
  HTML page:      https://secwatch.observer/filing/0000078003-25-000167

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer